(Q57880260)

English

Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3

article

In more languages

Statements

scholarly article

0 references

Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3 (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert L. Murphy

object named as

Robert Murphy

4

0 references

Bonaventura Clotet Sala

2

object named as

Bonaventura Clotet

0 references

author name string

Anita Rachlis

1

0 references

John Baxter

3

0 references

Eric Lefebvre

5

0 references

publication date

August 2007

0 references

HIV Clinical Trials

0 references

8

0 references

4

0 references

213-220

0 references

Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Epidemiology of viral hepatitis and HIV co-infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Hepatitis C virus/human immunodeficiency virus coinfection: clinical management issues

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Liver enzymes elevation after HAART in HIV-HCV co-infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT0804-213

21 January 2018

Identifiers

10.1310/HCT0804-213

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57880260&oldid=1584519301"